Neurocrine Operating Income from 2010 to 2025

NBIX Stock

USD 117.59 1.69 1.46%

Neurocrine Biosciences Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Neurocrine Biosciences generates from its operations. View All Fundamentals

Operating Income

First Reported

1996-03-31

Previous Quarter

183.8 M

Current Value

142 M

Quarterly Volatility

49.1 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 7.4 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.

Check out the analysis of Neurocrine Biosciences Correlation against competitors.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Operating Income Growth Pattern

Below is the plot of the Operating Income of Neurocrine Biosciences over the last few years. Operating Income is the amount of profit realized from Neurocrine Biosciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Neurocrine Biosciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Neurocrine Biosciences' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Neurocrine Operating Income Regression Statistics

	Arithmetic Mean	124,532,125
	Coefficient Of Variation	186.21
	Mean Deviation	191,581,016
	Median	36,895,000
	Standard Deviation	231,890,928
	Sample Variance	53773.4T
	Range	746.4M
	R-Value	0.80
	Mean Square Error	20698.2T
	R-Squared	0.64
	Significance	0.0002
	Slope	38,988,185
	Total Sum of Squares	806601T

Neurocrine Operating Income History

	2025	599 M
	2024	570.5 M
	2023	250.9 M
	2022	249 M
	2021	196.9 M
	2020	318.9 M
	2019	219.1 M

Other Fundumenentals of Neurocrine Biosciences

Non Operating Income Net Other

Neurocrine Biosciences Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.47	0.62	0.99	0.98	0.97	0.99	0.58	0.87	0.94	0.77	0.58	0.89	0.83	0.96	0.83	0.54	0.98	-0.8	0.74	-0.73	0.83	0.92
Total Stockholder Equity	0.99		0.42	0.67	0.98	0.99	0.93	0.97	0.54	0.86	0.92	0.7	0.55	0.86	0.86	0.98	0.8	0.5	0.97	-0.84	0.73	-0.72	0.86	0.93
Net Debt	0.47	0.42		0.13	0.5	0.47	0.56	0.49	0.76	0.22	0.48	0.6	0.25	0.48	0.41	0.32	0.44	0.34	0.55	0.05	0.23	-0.24	0.14	0.28
Retained Earnings	0.62	0.67	0.13		0.67	0.7	0.48	0.54	0.18	0.57	0.45	0.13	-0.14	0.46	0.75	0.64	0.24	0.26	0.6	-0.74	0.52	-0.38	0.67	0.71
Accounts Payable	0.99	0.98	0.5	0.67		0.99	0.95	0.97	0.65	0.85	0.92	0.72	0.52	0.88	0.84	0.93	0.79	0.53	0.97	-0.76	0.75	-0.66	0.8	0.89
Net Receivables	0.98	0.99	0.47	0.7	0.99		0.92	0.97	0.59	0.84	0.92	0.67	0.51	0.85	0.9	0.96	0.77	0.49	0.95	-0.8	0.69	-0.68	0.84	0.91
Total Liab	0.97	0.93	0.56	0.48	0.95	0.92		0.97	0.66	0.84	0.94	0.89	0.61	0.92	0.72	0.89	0.86	0.61	0.96	-0.68	0.73	-0.73	0.74	0.85
Total Current Assets	0.99	0.97	0.49	0.54	0.97	0.97	0.97		0.62	0.87	0.97	0.82	0.64	0.92	0.81	0.96	0.88	0.58	0.95	-0.75	0.66	-0.76	0.82	0.88
Short Term Debt	0.58	0.54	0.76	0.18	0.65	0.59	0.66	0.62		0.4	0.68	0.65	0.38	0.6	0.42	0.41	0.55	0.43	0.58	-0.08	0.33	-0.17	0.18	0.42
Intangible Assets	0.87	0.86	0.22	0.57	0.85	0.84	0.84	0.87	0.4		0.81	0.68	0.52	0.91	0.66	0.9	0.75	0.66	0.8	-0.79	0.62	-0.79	0.8	0.83
Short Term Investments	0.94	0.92	0.48	0.45	0.92	0.92	0.94	0.97	0.68	0.81		0.82	0.66	0.89	0.75	0.89	0.87	0.6	0.88	-0.66	0.61	-0.75	0.76	0.81
Long Term Debt	0.77	0.7	0.6	0.13	0.72	0.67	0.89	0.82	0.65	0.68	0.82		0.65	0.85	0.43	0.68	0.84	0.64	0.76	-0.4	0.49	-0.69	0.52	0.6
Common Stock	0.58	0.55	0.25	-0.14	0.52	0.51	0.61	0.64	0.38	0.52	0.66	0.65		0.61	0.3	0.59	0.88	0.46	0.55	-0.33	0.48	-0.57	0.54	0.51
Property Plant Equipment	0.89	0.86	0.48	0.46	0.88	0.85	0.92	0.92	0.6	0.91	0.89	0.85	0.61		0.6	0.88	0.88	0.71	0.85	-0.62	0.61	-0.8	0.72	0.77
Current Deferred Revenue	0.83	0.86	0.41	0.75	0.84	0.9	0.72	0.81	0.42	0.66	0.75	0.43	0.3	0.6		0.83	0.55	0.29	0.8	-0.75	0.48	-0.55	0.81	0.79
Net Tangible Assets	0.96	0.98	0.32	0.64	0.93	0.96	0.89	0.96	0.41	0.9	0.89	0.68	0.59	0.88	0.83		0.82	0.5	0.92	-0.88	0.66	-0.79	0.9	0.92
Capital Surpluse	0.83	0.8	0.44	0.24	0.79	0.77	0.86	0.88	0.55	0.75	0.87	0.84	0.88	0.88	0.55	0.82		0.66	0.8	-0.54	0.63	-0.74	0.74	0.74
Deferred Long Term Liab	0.54	0.5	0.34	0.26	0.53	0.49	0.61	0.58	0.43	0.66	0.6	0.64	0.46	0.71	0.29	0.5	0.66		0.49	-0.28	0.47	-0.61	0.51	0.49
Long Term Investments	0.98	0.97	0.55	0.6	0.97	0.95	0.96	0.95	0.58	0.8	0.88	0.76	0.55	0.85	0.8	0.92	0.8	0.49		-0.74	0.79	-0.68	0.78	0.87
Long Term Debt Total	-0.8	-0.84	0.05	-0.74	-0.76	-0.8	-0.68	-0.75	-0.08	-0.79	-0.66	-0.4	-0.33	-0.62	-0.75	-0.88	-0.54	-0.28	-0.74		-0.6	0.63	-0.86	-0.89
Net Invested Capital	0.74	0.73	0.23	0.52	0.75	0.69	0.73	0.66	0.33	0.62	0.61	0.49	0.48	0.61	0.48	0.66	0.63	0.47	0.79	-0.6		-0.53	0.68	0.75
Short Long Term Debt	-0.73	-0.72	-0.24	-0.38	-0.66	-0.68	-0.73	-0.76	-0.17	-0.79	-0.75	-0.69	-0.57	-0.8	-0.55	-0.79	-0.74	-0.61	-0.68	0.63	-0.53		-0.82	-0.68
Net Working Capital	0.83	0.86	0.14	0.67	0.8	0.84	0.74	0.82	0.18	0.8	0.76	0.52	0.54	0.72	0.81	0.9	0.74	0.51	0.78	-0.86	0.68	-0.82		0.89
Capital Stock	0.92	0.93	0.28	0.71	0.89	0.91	0.85	0.88	0.42	0.83	0.81	0.6	0.51	0.77	0.79	0.92	0.74	0.49	0.87	-0.89	0.75	-0.68	0.89

Click cells to compare fundamentals

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	570.5 M	599 M
Non Operating Income Net Other	-25.2 M	-23.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Operating Income from 2010 to 2025

Latest Neurocrine Biosciences' Operating Income Growth Pattern

Neurocrine Operating Income Regression Statistics

Neurocrine Operating Income History

Other Fundumenentals of Neurocrine Biosciences

Neurocrine Biosciences Operating Income component correlations

About Neurocrine Biosciences Financial Statements

Also Currently Popular

Additional Tools for Neurocrine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY